DEXYCU® (dexamethasone intraocular suspension)

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg

Life at EyePoint Pharma

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Silicon Valley Bank

Ocumension Therapeutics

RA Capital Management

Essex Woodlands Healthcare Partners

EW Healthcare Partners

Rosalind Advisors

EyePoint Pharmaceuticals

Google Maps

Amazon

DNSSEC

GoDaddy DNS

Microsoft

AWS Global Accelerator

COVID-19

IPv6

Akamai Hosted

Mimecast

Senior Vice President, Chief Medical Officer

Dario A. Paggiarino

Chief Financial Officer and Head of Corporate Development

George Elston

Chief People Officer & SVP, Information Technology

Jennifer Leonard

Executive Vice Chair EyePoint Pharmaceuticals

Nancy L.

Chief Executive Officer

Nancy Lurker

President & Chief Executive Officer

Paul Ashton

Senior Vice President and Chief Technology Officer

Said Saim

Vice President of Quality

Diane Shay

Vice President, Clinical Operations

Ellie Smith

VP, Head of Information Technology

Felix Izquierdo, ITIL

Wendy Dicicco

Ye Liu

President, Chief Executive Officer and a Director

Michael C. Pine

Chief Corporate Development & Strategy Officer

Jay Duker

President and Chief Executive Officer

Executive Vice Chair

Ron Honig

Chief Legal Officer & Company Secretary

East Coast Public Companies With More Than $10M in Revenue

Health Care Public Companies With More Than $1M in Revenue

United States Public Companies

Greater Boston Area Medical Companies

EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.

Post-IPO Equity - EyePoint Pharmaceuticals

Post-IPO Debt - EyePoint Pharmaceuticals

Debt Financing - EyePoint Pharmaceuticals

Watertown

Massachusetts

United States

North America

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals files for $400M mixed securities shelf (NASDAQ:EYPT)

EyePoint reveals Phase 3 plans for wet AMD treatment

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges

EyePoint’s stock plunges as eye treatment fails to meet trial goal

Philippines

Asia

India

Bangladesh

HTML5

GoDaddy Premium DNS

Vimeo

jQuery

Google Fonts

Google Tag Manager

F5 NGINX

Wordpress

Google Analytics

Microsoft Outlook

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	97a470c4
crunchbase profile	general	Oct 28, 2024 1:53 PM	b001109a
li profile	general	Feb 4, 2024 12:52 AM	3ee5718d
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	58a2d7bd
peers	general	Feb 4, 2024 12:52 AM	b36d4606
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EYEPOINTPHARMA

EyePoint Pharmaceuticals

Last Close

8.35

22/11 21:00

Market Cap

452.61M

Beta: -

Volume Today

1.10M

Avg: -